BIODEXA PHARMACEUTICALS-ADR(NASDAQ:BDRX) stock News

BDRX Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

a month ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change Effective

a month ago - By: ACCESS Newswire

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

a month ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change

a month ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

2 months ago - By: Biodexa Pharmaceuticals PLC

Results of Annual General Meeting

3 months ago - By: Biodexa Pharmaceuticals PLC

Result of General Meeting

3 months ago - By: Biodexa Pharmaceuticals PLC

Shareholder Update

4 months ago - By: Biodexa Pharmaceuticals PLC

Result of General Meeting

2 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

2 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

2 months ago - By: Benzinga - Mentions: RFL GOVX GALT APVO ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

2 months ago - By: Benzinga - Mentions: GOVX SNTI CBIO HSDT ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

2 months ago - By: ACCESS Newswire

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

3 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

3 months ago - By: Yahoo Finance - Mentions: RY RY.CA SEDG PATH ...

UiPath price target raised to $15 from $12 at TD Cowen

3 months ago - By: Yahoo Finance - Mentions: HRI HEES PD PATH ...

Herc Holdings, H&E Equipment announce expiration of tender offer

3 months ago - By: Yahoo Finance - Mentions: BLRX SEDG PD WETO ...

BioLineRx upgraded to Buy from Hold at JonesResearch

3 months ago - By: Yahoo Finance - Mentions: RY RY.CA SPWR PD ...

PagerDuty price target lowered to $17 from $18 at TD Cowen

3 months ago - By: Yahoo Finance - Mentions: RY RY.CA ULTA ZS ...

Zscaler price target raised to $290 from $245 at Evercore ISI

3 months ago - By: Yahoo Finance - Mentions: DHI CMG

Biodexa Pharmaceuticals sees cash runway into 1Q26

3 months ago - By: Yahoo Finance - Mentions: LMT JPM SEDG LHX ...

L3Harris Technologies price target raised to $270 from $240 at TD Cowen

3 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

3 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

3 months ago - By: Zacks Investment Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

4 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

4 months ago - By: Zacks Investment Research

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock

5 months ago - By: Biodexa Pharmaceuticals PLC

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock News

BDRX Latest News, Press Relases and Analysis

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Result of General Meeting

Shareholder Update

Result of General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

UiPath price target raised to $15 from $12 at TD Cowen

Herc Holdings, H&E Equipment announce expiration of tender offer

BioLineRx upgraded to Buy from Hold at JonesResearch

PagerDuty price target lowered to $17 from $18 at TD Cowen

Zscaler price target raised to $290 from $245 at Evercore ISI

Biodexa Pharmaceuticals sees cash runway into 1Q26

L3Harris Technologies price target raised to $270 from $240 at TD Cowen

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock

Preliminary Results for the Year Ended 31 December 2024